Patents Assigned to St. Pharm Co., Ltd.
  • Publication number: 20220235011
    Abstract: Provided is a phthalazinone compound, or a racemate, steroisomer or pharmaceutically acceptable salt thereof; a pharmaceutical composition for the prevention or treatment of Sirt6-associated diseases, including as an active ingredient, a phthalazinone compound, or a racemate, steroisomer or pharmaceutically acceptable salt thereof; and a method for treating Sirt6-associated diseases including administering a phthalazinone compound, or a racemate, steroisomer or pharmaceutically acceptable salt thereof to a subject in need.
    Type: Application
    Filed: May 29, 2020
    Publication date: July 28, 2022
    Applicants: ST PHARM CO., LTD., KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Kyungjin KIM, Kwangrok KIM, Uk-Il KIM, Hyung Tae BANG, Seul Ki LEE, Kwan-Young JEONG, Seung Kyu KANG, Heejung JUNG, Sang Dal RHEE, Won Hoon JUNG, Jun Mi LEE
  • Patent number: 11214570
    Abstract: Provided is a novel pyrrolopyridine compound represented by Chemical Formula I, a racemate or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; and to a method for preparing the same. A compound represented by Chemical Formula I shows high selectivity and antiviral activity against human immunodeficiency virus (HIV), with low toxicity; therefore, it is useful as a therapeutic agent for viral infection, in particular, HIV infection.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: January 4, 2022
    Assignee: ST PHARM CO., LTD.
    Inventors: Bong Jin Kim, Ill Young Lee, Jae Hak Kim, Hong Suk Shin, Jong Chan Son, Chong-Kyo Lee, Kyungjin Kim, Uk-Il Kim, Hwa Jung Nam
  • Patent number: 11149033
    Abstract: The present invention relates to a novel heteroaryl compound, an enantiomer, a diastereomer or a pharmaceutically acceptable salt thereof, and an antiviral composition comprising the same as an active ingredient. The novel compounds represented by formula (I) or formula (II) according to the present invention are remarkably superior in antiviral activity against an influenza virus, and furthermore, have low cytotoxicity and thus low adverse effects on a human body. Therefore, a pharmaceutical composition containing the same as an active ingredient can be effectively used for the prevention or treatment of diseases caused by an influenza virus infection.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: October 19, 2021
    Assignees: INSTITUT PASTEUR KOREA, ST PHARM CO., LTD.
    Inventors: Ji Young Min, So Young Chang, Ji Hye Lee, Sun Hee Kang, Sun Ju Kong, Su Yeon Jo, Young Mi Kim, Junghwan Choi
  • Patent number: 11059852
    Abstract: The present invention provides ergostenol glycoside derivatives, method for preventing, treating, or alleviating dermatitis using the same. The present invention also provides a method for preparing the ergostenol and glycoside derivatives thereof. The ergostenol and the glycoside derivatives thereof according to the present invention suppress the production of chemokines increasing according to the skin inflammation stimulation and inhibit the activity of transcriptional factors controlling the expression of various inflammation mediators in the prevention and treatment of dermatitis.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: July 13, 2021
    Assignee: ST PHARM CO., LTD.
    Inventors: Hakwon Kim, Tae Hoon Lee, Hoongyu Park, Hyunjeong Oh
  • Publication number: 20200377498
    Abstract: Provided is a novel pyrrolopyridine compound represented by Chemical Formula I, a racemate or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; and to a method for preparing the same. A compound represented by Chemical Formula I shows high selectivity and antiviral activity against human immunodeficiency virus (HIV), with low toxicity; therefore, it is useful as a therapeutic agent for viral infection, in particular, HIV infection.
    Type: Application
    Filed: March 24, 2017
    Publication date: December 3, 2020
    Applicant: ST PHARM CO., LTD.
    Inventors: Bong Jin KIM, Ill Young LEE, Jae Hak KIM, Hong Suk SHIN, Jong Chan SON, Chong-Kyo LEE, Kyungjin KIM, Uk-Il KIM, Hwa Jung NAM
  • Patent number: 10702859
    Abstract: The present disclosure provides a method for preparing ((2,2-dimethyl-1,3-dioxane-5,5-diyl)bis(methylene))bis(bis(2-methoxyphenyl)phosphine), a ligand for a polyketone polymerization catalyst, under mild conditions with high purity and high yield. Therefore, the preparation method of the present disclosure can be easily applied to mass production.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: July 7, 2020
    Assignee: ST PHARM CO., LTD.
    Inventors: Geun Jho Lim, Sun Ki Chang, Hyun Woo Baek, Jun Hyun Oh, Yeong Hun Kim
  • Patent number: 10702546
    Abstract: The present invention relates to a method for preparing an end site-specific macromolecule-bile acid oligomer conjugate, comprising conjugating a bile acid oligomer which is prepared by oligomerization of two or more bile acid monomers to the terminal site of a macromolecule; a method for body absorption of an end site-specific macromolecule-bile acid oligomer conjugate, comprising administering the macromolecule-bile acid oligomer conjugate prepared by the above method to a subject orally; an end site-specific macromolecule-bile acid oligomer conjugate wherein the bile acid oligomer is conjugated to the terminal site of macromolecule; a composition comprising the conjugate; an oral formulation for macromolecule comprising the conjugate, a solubilizer, an excipient, a disintegrant, a binder, and a lubricant; a pharmaceutical composition comprising a heparin-bile acid oligomer conjugate wherein the bile acid oligomer is conjugated to the terminal site of heparin; and a method for treating thrombosis using said
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: July 7, 2020
    Assignee: ST PHARM CO., LTD.
    Inventors: Young Ro Byun, Al-Hilal Taslim Ahmed, Ok Cheol Jeon, Hyun Tae Moon, Kyungjin Kim, Jisuk Yun
  • Patent number: 10538504
    Abstract: Disclosed is a method of preparing an intermediate for an oxazolidinone derivative, which enables 5-bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine to be produced at high yield and high purity, thus exhibiting high preparation efficiency under optimal processing conditions and making it suitable for industrial mass production.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: January 21, 2020
    Assignee: ST PHARM CO., LTD.
    Inventors: Seok Hun Woo, YunHee Choi, Hong Jun Kim, Sun Ki Chang, Geun Jho Lim
  • Patent number: 10501403
    Abstract: The present invention relates to a novel method for preparing (S)—N1-(2-aminoethyl)-3-(4-alkoxyphenyl)propane-1,2-diamine trihydrochloride.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: December 10, 2019
    Assignee: ST PHARM CO., LTD.
    Inventors: Yeong Hun Kim, Hyun Woo Baek, Hyeon Jin Lee, Sang Kyu Kang, Sun Ki Chang, Geun Jho Lim
  • Publication number: 20190337976
    Abstract: The present invention provides ergostenol glycoside derivatives, method for preventing, treating, or alleviating dermatitis using the same. The present invention also provides a method for preparing the ergostenol and glycoside derivatives thereof. The ergostenol and the glycoside derivatives thereof according to the present invention suppress the production of chemokines increasing according to the skin inflammation stimulation and inhibit the activity of transcriptional factors controlling the expression of various inflammation mediators in the prevention and treatment of dermatitis.
    Type: Application
    Filed: July 22, 2019
    Publication date: November 7, 2019
    Applicant: ST PHARM CO., LTD.
    Inventors: Hakwon KIM, Tae Hoon LEE, Hoongyu PARK, Hyunjeong OH
  • Patent number: 10428096
    Abstract: Provided are a novel polyketone polymerization catalyst and a method of preparing a ligand, which can reduce production costs and can enable commercial mass synthesis by using ((2,2-dimethyl-1,3-dioxane-5,5-diyl)bis(methylene))bis(bis(2-methoxyphenyl)phosphine) as a ligand constituting the polykeytone polymerization catalyst, the ligand having a simple structure and a small molecular weight while having high activity.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: October 1, 2019
    Assignees: HYOSUNG CHEMICAL CORPORATION, ST PHARM CO., LTD.
    Inventors: Jae Yoon Shim, Sun Kue Kim, Hae Souk Cho, Ji Hwan Choi, Geun Jho Lim, Sun Ki Chang, Min Kyu Kim, In Hyeok Baek
  • Patent number: 10336765
    Abstract: The present invention relates to a novel dihydropyranopyrimidinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: July 2, 2019
    Assignee: ST. PHARM CO., LTD.
    Inventors: Kyungjin Kim, Uk-Il Kim, Ji Hye Yoon
  • Patent number: 10179785
    Abstract: The present invention relates to a novel imidazotriazinone or imidazopyrazinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: January 15, 2019
    Assignee: ST PHARM CO., LTD.
    Inventors: Jung Nyoung Heo, Hwan Jung Lim, Kwang Rok Kim, Kyung Jin Kim, Uk Il Kim, Hyung Tae Bang, Ji Hye Yoon
  • Patent number: 10065933
    Abstract: The present disclosure relates to a novel method for preparing high-purity gadobutrol. The present disclosure can be easily applied to a large scale production because purity of intermediate can be managed via simple and mild process and accordingly, high-purity or ultra high-purity gadobutrol that has higher purity than previous gadobutrol can be prepared in high yield therethrough.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: September 4, 2018
    Assignee: ST PHARM CO., LTD.
    Inventors: Geun Jho Lim, Sun Ki Chang, Chang Ho Byeon, Hoe Jin Yoon, Moon Soo Kim
  • Patent number: 9914737
    Abstract: The present invention relates to a novel triazolopyrimidinone or triazolopyridinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: March 13, 2018
    Assignee: ST PHARM CO., LTD.
    Inventors: Jung Nyoung Heo, Hwan Jung Lim, Kwang Rok Kim, Kyung Jin Kim, Uk Il Kim, Hyung Tae Bang, Ji Hye Yoon
  • Publication number: 20170342038
    Abstract: The present disclosure relates to a novel method for preparing high-purity gadobutrol. The present disclosure can be easily applied to a large scale production because purity of intermediate can be managed via simple and mild process and accordingly, high-purity or ultra high-purity gadobutrol that has higher purity than previous gadobutrol can be prepared in high yield therethrough.
    Type: Application
    Filed: December 28, 2015
    Publication date: November 30, 2017
    Applicant: ST PHARM CO., LTD.
    Inventors: Geun Jho LIM, Sun Ki CHANG, Chang Ho BYEON, Hoe Jin YOON, Moon Soo Kim
  • Patent number: 9822084
    Abstract: Disclosed is a novel method of preparing highly pure calcobutrol using an intermediate (butrol) of gadobutrol without using highly pure gadobutrol. This method is capable of obtaining calcobutrol at high purity and high yield through a simple and environmentally friendly process, and thus can be easily applied to mass production.
    Type: Grant
    Filed: September 7, 2015
    Date of Patent: November 21, 2017
    Assignee: ST PHARM CO., LTD.
    Inventors: Geun Jho Lim, Sun Ki Chang, Chang Ho Byeon, Hoe Jin Yoon, Moon Soo Kim
  • Patent number: 9790170
    Abstract: The present invention provides a novel method for preparing lacosamide with high chiral purity from D-serine. The method of the present invention can obtain lacosamide with high chiral purity in a high yield through a simple and environmentally-friendly process and thus can be easily applied to mass production.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: October 17, 2017
    Assignee: ST PHARM CO., LTD.
    Inventors: Geun Jho Lim, Sun Ki Chang, Jae Hun Kim, Jong Moon Park
  • Patent number: 9006436
    Abstract: The present invention provides a method which enables the simple, economical and high-yield production which is a key intermediate of antidiabetic drug Januvia.
    Type: Grant
    Filed: January 18, 2012
    Date of Patent: April 14, 2015
    Assignee: ST Pharm Co., Ltd.
    Inventors: Geun Gho Lim, Sun Ki Chang, Chang Ho Byeon
  • Patent number: 8901289
    Abstract: The present invention provides a method for preparing nucleotide oligomers, including (a) coupling a nucleotide dimer or nucleotide trimer to a nucleoside attached to solid supports or to universal solid supports as a starting material; (b) sequentially coupling nucleotide monomers to the resulting structures of Step (a) to prepare a nucleotide oligomer; and (c) removing the nucleotide oligomers from the solid supports. The method of the present invention provides nucleotide oligomers having 15-20% higher purity than the conventional art. The present invention enables the efficient and inexpensive synthesis of nucleotide oligomers with high purity within a shorter period of time.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: December 2, 2014
    Assignee: St. Pharm Co., Ltd.
    Inventors: Kyeong-Eun Jung, Alexei Kayushin, Moon Hee Kim, Kyung-Il Kim, Sungwon Kim, Yumi Ji